RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access

According to Ars Technica, Robert F. Kennedy Junior, now in his Health and Human Services role, is stacking FDA advisory panels with advocates who promote peptide drugs. The move contradicts concerns from FDA scientists, who warn that many peptide therapies remain untested and could pose health risks. Peptides have become trendy in wellness circles, but the FDA's own experts are opposed to loosening access until safety and efficacy are properly established. The conflict highlights growing tensions between Kennedy's deregulatory agenda and institutional caution at the agency.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton